| Study/year | Design/domain | Key quantitative or mechanistic result | Exact verbatim sentence(s) from the available abstract | DOI/URL | PMID |
|---|---|---|---|---|---|
| van de Laar et al., 2011, *Nature Genetics* | Seminal discovery; human genetics/clinical syndrome definition | Discovery study establishing SMAD3 as cause of syndromic aortic aneurysm/dissection with early-onset osteoarthritis; abstract not available in retrieved text. (pqac-00000011) | Abstract unavailable in retrieved text; do not quote. | DOI: 10.1038/ng.744; https://doi.org/10.1038/ng.744 | not available in retrieved text |
| Tan et al., 2013, *J Am Heart Assoc* | Mouse mechanism; inflammation/biomechanics/iNOS-MMP axis | States ~90% of patients with distinct SMAD3 mutations develop aneurysm/dissection; in mice, AngII-driven inflammation rather than hypertension caused aneurysm/dissection/rupture; mechanism implicated macrophage iNOS and MMP2/9. (pqac-00000006) | “Ninety percent of the patients carrying distinct SMAD3 mutations develop aortic aneurysms and dissections, called aneurysms‐osteoarthritis syndrome (AOS).” “We have shown that angiotensin II–induced vascular inflammation, but not hypertension, leads to aortic aneurysms and dissections, ultimately causing aortic rupture and death in mice.” “Chromatin immunoprecipitation (ChIP) and re‐ChIP assays revealed that the underlying mechanism involved aberrant upregulation of inducible nitric oxide synthase (iNOS)–derived nitric oxide production and activation of elastolytic matrix metalloproteinases 2 and 9.” “Administration of clodronate‐liposomes and iNOS inhibitor completely abrogated these aortic conditions, thereby identifying iNOS‐mediated nitric oxide secretion from macrophages as the downstream event of SMAD3 that drives this severe pathology.” | DOI: 10.1161/JAHA.113.000269; https://doi.org/10.1161/jaha.113.000269 | not available in retrieved text |
| van der Pluijm et al., 2016, *EBioMedicine* | Mouse mechanism; remodeling/TGF-β paradox/ECM-VSMC biology | Smad3 deficiency caused rapid aneurysm growth and premature death; paradoxical increased pSmad2/pERK without downstream transcriptional activation; medial elastin disruption/adventitial inflammation; suggests immune suppression may be more beneficial than targeting TGF-β signaling. (pqac-00000002, pqac-00000001) | “Aneurysm-osteoarthritis syndrome characterized by unpredictable aortic aneurysm formation, is caused by SMAD3 mutations.” “Smad3−/−animals developed aortic aneurysms rapidly, resulting in premature death.” “Aortic wall immunohistochemistry showed no increase in extracellular matrix and collagen accumulation, nor loss of vascular smooth muscle cells (VSMCs) but instead revealed medial elastin disruption and adventitial inflammation.” “Although Smad3−/−aortas showed increased nuclear pSmad2 and pErk, indicating TGF-β receptor activation, downstream TGF-β-activated target genes were not upregulated.” “Increased pSmad2 and pErk staining in pre-aneurysmal Smad3−/−aortas implied that aortic damage and TGF-β receptor-activated signaling precede aortic inflammation.” “Smad3 deficiency leads to imbalanced activation of downstream genes, no activation of MMPs in VSMCs, and immune responses resulting in rapid aortic wall dilatation and rupture.” | DOI: 10.1016/j.ebiom.2016.09.006; https://doi.org/10.1016/j.ebiom.2016.09.006 | not available in retrieved text |
| de Wagenaar et al., 2024, *Human Molecular Genetics* / preprint text retrieved | Human cohort + patient-derived fibroblasts/VSMCs; genotype-phenotype | LDS3/AOS phenotype is highly variable; DN MH2 variants trended to more major events and younger first event than haploinsufficient variants; functional differences in differentiation, SMA/MYH11, and ECM formation. (pqac-00000004, pqac-00000005) | “Pathogenic (P) and likely pathogenic (LP) variants in the SMAD3 gene cause Loeys-Dietz syndrome type 3 (LDS3), also known as aneurysms-osteoarthritis syndrome (AOS).” “The phenotype of LDS3 is highly variable and characterized by arterial aneurysms, dissections and tortuosity throughout the vascular system combined with skeletal, cutaneous and facial features.” “Individuals with dominant negative (DN) variants in the MH2 protein interaction domain of SMAD3 exhibited a higher frequency of major events (66.7% vs. 44.0%, p=0.054), occurring at a younger age compared to those with haploinsufficient (HI) variants.” “Moreover, the age at the onset of the first major event was notably younger in individuals with DN variants in MH2, 35.0 years [IQR 29.0-47.0], compared to 46.0 years [IQR 40.0-54.0] in those with HI variants (p=0.065).” “Conversely, DN SMAD3 variant myofibroblasts demonstrated reduced extracellular matrix (ECM) formation compared to control cell lines.” | DOI/URL in retrieved text: https://doi.org/10.1101/2023.12.11.571192 | not available in retrieved text |
| Monda et al., 2023, *Diagnostics* | Contemporary management review summarizing LDS/HTAD guidance | Review states LDS requires whole-body imaging at diagnosis and 6-month follow-up to assess enlargement; recommends beta-blockers and/or ARBs from diagnosis; individualized surgery thresholds; TEVAR generally not recommended. (pqac-00000008) | “Thus, the 2022 ACC/AHA guidelines for aortic diseases recommend whole body imaging (from cerebral circulation to pelvis) in all patients with LDS at diagnosis and six monthly afterwards to establish if enlargement is occurring [5].” “Currently, 2022 ACC/AHA guidelines for aortic disease recommend starting beta-blockers and/or ARBs at the time of diagnosis in order to reduce aortic growth rate and reduce the occurrence of aortic events [5].” “Thus, according to the 2022 ACC/AHA guidelines, the thresholds for aortic surgery should be individualized according to the type of mutations and presence of additional risk factors [5].” “Endovascular aneurysm repair (TEVAR) is not recommended in these patients because progressive aneurysm development may generate a false lumen and result in graft failure.” | DOI: 10.3390/diagnostics13040772; https://doi.org/10.3390/diagnostics13040772 | not available in retrieved text |
| Spaziani et al., 2024, *Diagnostics* | Contemporary management review; pregnancy/exercise in HTAD | Review summarizes pregnancy counseling, imaging, BP control, avoidance of ARBs in pregnancy, and avoidance of power sports in HTAD including LDS-risk contexts. (pqac-00000009, pqac-00000010) | “All women with HTAD should undergo pre-conceptional counselling from adolescence about the risks of aortic dissection related to pregnancy, and appropriate aortic imaging with transthoracic echocardiography, cardiac magnetic resonance or computed tomography is recommended [5].” “Strict control of blood pressure is advised to prevent values exceeding 130/80 mmHg. BBs are the drug of choice for the treatment of systemic hypertension, while ARBs are contraindicated in pregnancy due to fetal toxicity [64].” “Generally, power exercises are not recommended, while skill sports with a lower impact on blood pressure are preferred [75].” | DOI: 10.3390/diagnostics14010112; https://doi.org/10.3390/diagnostics14010112 | not available in retrieved text |
| Asta et al., 2023, *Int J Environ Res Public Health* | Contemporary management review; medical therapy/prognosis in syndromic aortopathies | Review states β-blockers and sartans remain first-line; losartan reduces SMAD2 phosphorylation/ERK signaling; prognosis improved with earlier diagnosis/follow-up. (pqac-00000012) | “According to the latest American guidelines, β-blockers and sartans continue to be the drugs of first choice in the treatment of SADs [28].” “Losartan, an angiotensin II receptor antagonist, reduces the phosphorylation of SMAD2 and inhibits the ERK-2 kinase pathway, resulting in a negative regulation of TGF-β [59].” “The life expectancy of patients affected by SADs has certainly undergone a significant improvement in the last 20 years thanks to ever earlier genetic diagnoses, more defined follow-up programs, and therefore the possibility of performing elective surgery.” | DOI: 10.3390/ijerph20166615; https://doi.org/10.3390/ijerph20166615 | not available in retrieved text |


*Table: This table compiles pivotal discovery, mechanistic, genotype-phenotype, and management sources for SMAD3-related aneurysm-osteoarthritis syndrome using only quotations and identifiers available in retrieved text. It is designed to support a fully cited final report while clearly separating primary evidence from contemporary review guidance.*